Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Cost-effectiveness analysis of benralizumab treatment based on severe exacerbations
| Mean (SD) per patient | Previous 12 months (baseline) | At 12 months on benralizumab |
|---|---|---|
| No. of exacerbations | 5.50 (2.63) | 0.66 (0.94) |
| Direct healthcare costs (in €) | 10,292 (7885) | 13,204 (2145) |
| Difference in | ||
| % reduction of exacerbations | 88.14 | |
| Costs (€) | 2912 | |
| Total cost to reduce 1 exacerbation (€) | 602 | |
| p value | < 0.001 | |
| Cost-effectiveness ratio | 3304 | |
| Cohen’s d | 2.00 (1.49–2.51) | |
